Tower Research Capital (TRC)’s NewGenIvf NIVF Stock Holding History

Tower Research Capital (TRC)’s Portfolio NIVF Stock Details NIVF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.36K	Buy	3,333 +2,833	+567%	+$10.9K	﹤0.01%	4282
2026 Q1	$3.39K	Buy	+500	New	+$6.06K	﹤0.01%	4322
2025 Q2	–	Hold	0	–	-$64	–	5629
2025 Q1	–	Hold	0	–	–	–	5064
2024 Q4	–	Hold	0	–	–	–	5422

Other funds holding NIVF

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Tower Research Capital (TRC)'s NIVF Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its NewGenIvf (NIVF) stake by 567% in Q2 2026, buying an estimated $10.9K and bringing the position to 3,333 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #4282.

Tower Research Capital (TRC) first reported a position in NIVF in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold NIVF as of Q2 2026.

Tower Research Capital (TRC) held 3,333 shares of NewGenIvf worth $5.36K as of Q2 2026.
Tower Research Capital (TRC) bought 2,833 NewGenIvf shares in Q2 2026, an estimated $10.9K.
NewGenIvf made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4282 holding.
Tower Research Capital (TRC) first reported a position in NewGenIvf in Q1 2026 and has held it in 2 quarters since.
5 funds tracked by Wall St. Rank held NewGenIvf as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.